Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-...

Dr Suresh Ramalingam speaks to ecancer at ASCO 2024 about results from the LAURA study which evaluated osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC.
He explains that patients were enrolled within 6 weeks of chemotherapy and radiation as long as they did not have disease progression and were randomised 2:1 osimertinib versus placebo.
Dr Ramalingam reports that the progression-free survival was 39.1 months with osimertinib vs 5.6 months with placebo establishing this treatment as a new standard of care.